- Home
- MSI vs CANF Comparison
MSI vs CANF Comparison
Compare MSI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSI
- CANF
- Stock Information
- Founded
- MSI 1928
- CANF 1994
- Country
- MSI United States
- CANF Israel
- Employees
- MSI N/A
- CANF N/A
- Industry
- MSI Radio And Television Broadcasting And Communications Equipment
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MSI Technology
- CANF Health Care
- Exchange
- MSI Nasdaq
- CANF Nasdaq
- Market Cap
- MSI N/A
- CANF 7.9M
- IPO Year
- MSI N/A
- CANF N/A
- Fundamental
- Price
- MSI $434.83
- CANF $1.04
- Analyst Decision
- MSI Strong Buy
- CANF Strong Buy
- Analyst Count
- MSI 9
- CANF 2
- Target Price
- MSI $506.89
- CANF $14.00
- AVG Volume (30 Days)
- MSI 928.8K
- CANF 422.0K
- Earning Date
- MSI 05-01-2025
- CANF 05-13-2025
- Dividend Yield
- MSI 1.00%
- CANF N/A
- EPS Growth
- MSI N/A
- CANF N/A
- EPS
- MSI 9.23
- CANF N/A
- Revenue
- MSI $10,817,000,000.00
- CANF $674,000.00
- Revenue This Year
- MSI $6.73
- CANF $461.72
- Revenue Next Year
- MSI $5.79
- CANF N/A
- P/E Ratio
- MSI $47.39
- CANF N/A
- Revenue Growth
- MSI 8.41
- CANF N/A
- 52 Week Low
- MSI $332.98
- CANF $1.22
- 52 Week High
- MSI $507.82
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MSI 56.95
- CANF 32.37
- Support Level
- MSI $421.53
- CANF $1.13
- Resistance Level
- MSI $438.14
- CANF $1.19
- Average True Range (ATR)
- MSI 8.04
- CANF 0.11
- MACD
- MSI 2.29
- CANF -0.02
- Stochastic Oscillator
- MSI 90.08
- CANF 1.24
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).